Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 138,853 shares, a decline of 53.3% from the September 30th total of 297,566 shares. Based on an average trading volume of 7,295,221 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Stock Performance
Shares of RGBP opened at $0.00 on Friday. Regen BioPharma has a twelve month low of $0.00 and a twelve month high of $0.02.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy applications. The company has historically described its work as targeting conditions involving bone marrow failure, cancer and immune-system dysfunction.
Its reported research programs have included HemaXellerate, an investigational approach intended to support the restoration of blood-forming cells, as well as programs involving cancer vaccines, immune modulation and the NR2F6 biological pathway.
Further Reading
- Five stocks we like better than Regen BioPharma
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
